CALIFORNIA TRANSPLANT SERVICES, INC.

California Transplant Services, Inc. specializes in the procurement, processing, and delivery of autologous bone tissue and other specialized transplantable biological materials for clinical use. Their core capabilities center on the handling of human tissue under strict aseptic and regulatory conditions, ensuring viability, sterility, and compliance with FDA and AABB standards. The company demonstrates technical expertise in tissue banking protocols, cryopreservation, quality control testing, and chain-of-custody documentation for transplant-ready grafts. Their focus on autologous sources indicates a niche specialization in patient-specific tissue recovery and preparation, minimizing immunogenic risk and enhancing transplant success rates. This precision-driven approach differentiates them in the high-stakes field of regenerative medicine and orthopedic reconstruction. The organization maintains a consistent relationship with the Department of Veterans Affairs, providing critical biological materials to support surgical interventions for combat-related injuries, degenerative bone conditions, and reconstructive procedures among veteran patients. Their work supports VA’s broader mission in advanced musculoskeletal care and trauma recovery, aligning with VA’s emphasis on evidence-based, patient-centered transplant therapies. California Transplant Services operates within the NAICS 621991 category for blood and organ banks, which in practice encompasses the end-to-end management of human tissue for transplantation—excluding whole organs. This positions them as a specialized supplier within the regenerative medicine supply chain, serving hospitals and surgical centers that require compliant, traceable, and clinically validated tissue grafts. As an 8H-certified entity based in Carlsbad, California, the company is structured as a small business with a focused operational footprint. While it holds no additional federal certifications, its geographic location places it within a major biotech and medical innovation corridor, enabling access to advanced laboratory infrastructure and clinical partners. The firm’s market positioning is that of a niche, high-compliance tissue services provider serving federal healthcare systems with specialized biological products.